Further studies demonstrated that the HSPPC-96 vaccine can improve the survival of GBM patients who undergo SOC and revealed that peripheral myeloid cell expression of PD-L1 might impact the antitumor efficacy of the vaccine [94]. The gene discussed is CD274; the disease is glioblastoma.